Login / Signup

SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.

Krista KinneerJohn MeekinArnaud C TiberghienYu-Tzu TaiSandrina PhippsChristine Mione KieferMarlon C RebelattoNazzareno DimasiAlyssa MoriartyKyriakos P PapadopoulosSriram SridharStephen J GregsonMichael J WickLuke MastersonKenneth C AndersonRonald HerbstPhilip W HowardDavid A Tice
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Our findings support SLC46A3 as a potential patient selection biomarker with immediate relevance to clinical trials involving these ADCs.
Keyphrases
  • clinical trial
  • human health
  • case report
  • randomized controlled trial
  • risk assessment
  • drug delivery
  • climate change
  • phase iii
  • double blind
  • placebo controlled